Alnylam Pharmaceuticals Inc.
) recently initiated a phase I study on ALN-TTRsc. ALN-TTRsc is a
ribo nucleic acid interference (RNAi) therapeutic that targets
transthyretin (TTR) for the treatment of TTR-mediated amyloidosis
The company is developing the candidate for the treatment of
familial amyloidotic cardiomyopathy (FAC). The company is
expected to enrol around 40 healthy volunteers for the study. The
study will evaluate the safety and tolerability of ALN-TTRsc in
The company expects data from the study in mid-2013. Depending
on the results from the phase I study, Alnylam plans to initiate
a phase II study on ALN-TTRsc in patients suffering from FAC by
the end of this year and a pivotal study for ALN-TTRsc in FAC
patients in 2014.
Alnylam is collaborating with Genzyme, a
) company, for the development and commercialization of RNAi
therapeutics in Japan and the broader Asian-Pacific region.
Alnylam is responsible for the same in North and South America,
Europe, and the rest of the world.
Earlier this year, Alnylam had provided a brief update on its
key "Alnylam 5x15" pipeline, which aims to develop RNAi
therapeutic candidates and partner programs for the next couple
of years. The company is expecting several study results and
initiations based on its RNAi therapeutic candidates in the next
We believe that the company is progressing well with its
"Alnylam 5x15" pipeline. We expect investor focus to stay on the
successful development of the pipeline, though most of the
candidates are in early stages of development.
Alnylam carries a Zacks Rank #3 (Hold). However, other
biopharmaceutical stocks such as
Array BioPharma Inc.
) currently carry a Zacks Rank #1 (Strong Buy) and Zacks Rank #2
ALNYLAM PHARMA (ALNY): Free Stock Analysis
ARRAY BIOPHARMA (ARRY): Free Stock Analysis
ATHERSYS INC (ATHX): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.